STATE OF CONNECTICUT DEPARTMENT OF SOCIAL SERVICES
TELEPHONE: 1-866-409-8386 FAX: 1-866-759-4110

CT Medical Assistance Program

CYSTIC FIBROSIS Prior Authorization (PA) Request Form

[To be used for the authorization of Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta]

To Be Completed By Prescriber

Prescriber Information	Patient Information
Prescriber NPI:	Patient Medicaid ID Number:
Prescriber Name:	Patient Name:
Prescriber Phone # ( )	Patient's Date of Birth (MM/DD/CCYY):
Prescriber Fax# ( )	

Clinical Information

Alyftrek: Is the patient 6 years of age or older and have a diagnosis of cystic fibrosis with at least one F508del mutation or another responsive mutation in the CFTR gene?	☐ Yes ☐ No
Kalydeco: Is the patient 1 month of age or older and have a diagnosis of cystic fibrosis with one mutation in the CFTR gene confirmed by a FDA-cleared CF mutation test or if the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use?	☐ Yes ☐ No
Orkambi: Is the patient 1 years of age or older and have a diagnosis of cystic fibrosis homozygous for the F508del mutation in the CFTR gene confirmed by an FDA-cleared CF mutation test?	☐ Yes ☐ No
Symdeko: Is the patient 6 years of age or older and have a diagnosis of cystic fibrosis homozygous for the F508del mutation in the CFTR gene confirmed by an FDA-cleared CF mutation test or have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence or if the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use?	☐ Yes ☐ No
Trikafta: Is the patient 2 years of age or older and have a diagnosis of cystic fibrosis have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene confirmed by a FDA-cleared CF mutation test or if the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data?	☐ Yes ☐ No

If you answered 'NO' to the question above corresponding to the requested medication above, a Letter of Medical Necessity (LMN) must be reviewed for consideration. Please provide all relevant information relating to the medical necessity (see Conn. Gen. Stat§ 17b-259b(a)) for the requested Cystic Fibrosis medication for this patient. Submit request via email to rx.lmn@ct.gov.

Please Note: Pharmacies should not be contacting prescribers to provide pre-signed PA forms or submitting pre-signed forms for PA, nor should prescribing providers be requesting that pharmacies perform PA activities for them. PA requests must originate from the prescriber, and only the prescriber should sign the form at the time of PA submission.

I certify that documentation is maintained in my files and the information given is true and accurate for the medication requested, subject to penalty under section 1To-99 of the Connecticut General Statutes and sections 17-83k-1- to 17-83k-7, inclusive, of the Regulations of Connecticut State Agencies. I certify that the above-referenced member is a patient under my clinic's/practice's ongoing care. Authorizations for Early Refill Requests are valid one time only.

Prescriber Signature* :_______________________________ **Date (MM/DD/CCYY).**______________

* Mandatory (others may not sign for prescriber). **In accordance with federal law, prescribers must be enrolled in the Connecticut Medical Assistance Program (CMAP). CMAP will not pay for prescriptions written by a non-enrolled provider.**

This form (and attachments) contains protected health information (PHI) for Gainwell Technologies and is covered by the Electronic Communications Privacy Act, 18 U.S.C. §2510-2521 and the Standards for Privacy of Individually Identifiable Health Information, 45 CFR Parts 160 and 164, which is intended only for the use of prior authorization. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited. Any unintended recipient should contact Gainwell Technologies by telephone at (860) 255-3900 or by e-mail immediately and destroy the original message.